Immuneering (IMRX) Share-based Compensation (2020 - 2026)
Immuneering (IMRX) posted quarterly Share-based Compensation of $1.6 million for Q1 2026, down 3.29% year-over-year from $1.7 million in Q1 2025, and little changed quarter-over-quarter from $1.6 million in Q4 2025.
Immuneering (IMRX) Share-based Compensation (2020 - 2026) Analysis & Trends
Immuneering's Share-based Compensation history runs 7 years deep, the most recent figure standing at $1.6 million for Q1 2026.
- In Q1 2026, Share-based Compensation fell 3.29% year-over-year to $1.6 million; the TTM figure through Mar 2026 stood at $6.3 million (down 6.9% YoY), while the FY2025 annual figure was $6.3 million, down 2.93% from the prior year.
- Share-based Compensation for Q1 2026 stood at $1.6 million, roughly flat from $1.6 million in the prior quarter.
- The five-year high for Share-based Compensation was $1.7 million in Q4 2024, with the low at $897650.0 in Q1 2022.
- The 5-year median for Share-based Compensation is $1.5 million (2023), against an average of $1.4 million.
- The sharpest annual moves came in 2022 and 2025: Share-based Compensation surged 392.61% in 2022, then fell 11.22% in 2025.
- Immuneering's Share-based Compensation stood at $1.0 million in 2022, then jumped by 56.52% to $1.6 million in 2023, then grew by 5.13% to $1.7 million in 2024, then declined by 5.04% to $1.6 million in 2025, then retreated by 0.07% to $1.6 million in 2026.
- Business Quant data shows IMRX's Share-based Compensation at $1.6 million in Q1 2026, $1.6 million in Q4 2025, and $1.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Immuneering | 327.37 Mn | 327.37 Mn | - | 1.63 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.63 Mn |
| Jun 30, 2026 | 1.63 Mn |
| Mar 31, 2026 | 1.64 Mn |
| Mar 31, 2026 | 1.64 Mn |
| Dec 31, 2025 | 1.64 Mn |
| Dec 31, 2025 | 1.64 Mn |
| Sep 30, 2025 | 1.46 Mn |
| Sep 30, 2025 | 1.46 Mn |
| Jun 30, 2025 | 1.52 Mn |
| Jun 30, 2025 | 1.52 Mn |
| Mar 31, 2025 | 1.69 Mn |
| Mar 31, 2025 | 1.69 Mn |
| Dec 31, 2024 | 1.72 Mn |
| Dec 31, 2024 | 1.72 Mn |
| Sep 30, 2024 | 1.64 Mn |
| Sep 30, 2024 | 1.64 Mn |
| Jun 30, 2024 | 1.66 Mn |
| Jun 30, 2024 | 1.66 Mn |
| Mar 31, 2024 | 1.47 Mn |
| Mar 31, 2024 | 1.47 Mn |